DK0792167T3 - Monofunktionelle og/eller polyfunktionelle polylysin-konjugater - Google Patents

Monofunktionelle og/eller polyfunktionelle polylysin-konjugater

Info

Publication number
DK0792167T3
DK0792167T3 DK95940329T DK95940329T DK0792167T3 DK 0792167 T3 DK0792167 T3 DK 0792167T3 DK 95940329 T DK95940329 T DK 95940329T DK 95940329 T DK95940329 T DK 95940329T DK 0792167 T3 DK0792167 T3 DK 0792167T3
Authority
DK
Denmark
Prior art keywords
pct
polylysine conjugates
diseases
monofunctional
polyfunctional
Prior art date
Application number
DK95940329T
Other languages
Danish (da)
English (en)
Inventor
Michel Geffard
Original Assignee
Michel Geffard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Michel Geffard filed Critical Michel Geffard
Application granted granted Critical
Publication of DK0792167T3 publication Critical patent/DK0792167T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK95940329T 1994-11-18 1995-11-17 Monofunktionelle og/eller polyfunktionelle polylysin-konjugater DK0792167T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9413861A FR2727117A1 (fr) 1994-11-18 1994-11-18 Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
PCT/FR1995/001517 WO1996015810A1 (fr) 1994-11-18 1995-11-17 Conjugues monofonctionnels et/ou polyfonctionnels de la polylysine

Publications (1)

Publication Number Publication Date
DK0792167T3 true DK0792167T3 (da) 2001-10-29

Family

ID=9468953

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95940329T DK0792167T3 (da) 1994-11-18 1995-11-17 Monofunktionelle og/eller polyfunktionelle polylysin-konjugater

Country Status (14)

Country Link
US (1) US6114388A (https=)
EP (1) EP0792167B1 (https=)
JP (1) JP4128618B2 (https=)
AT (1) ATE202487T1 (https=)
AU (1) AU694825B2 (https=)
CA (1) CA2205557C (https=)
DE (1) DE69521521T2 (https=)
DK (1) DK0792167T3 (https=)
ES (1) ES2161915T3 (https=)
FR (1) FR2727117A1 (https=)
GR (1) GR3036710T3 (https=)
NZ (1) NZ297040A (https=)
PT (1) PT792167E (https=)
WO (1) WO1996015810A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO104396A0 (en) 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Antiviral linear polymers
PT970114E (pt) 1997-04-18 2006-12-29 Novartis Ag Neoglicoproteínas
FR2763853B1 (fr) * 1997-05-28 2000-01-07 Oreal Association d'un retinoide avec un polymere polyamine
DE19732139C2 (de) * 1997-07-25 2002-10-10 Max Planck Gesellschaft Mesomorphe Komplexe aus Vitamin A-Säure und kationischen Polyelektrolyten, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
FR2773808B1 (fr) * 1998-01-20 2000-05-05 Sagebo Composes susceptibles de pieger les ions metalliques, leur procede d'obtention et leur utilisation
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
GB9811059D0 (en) * 1998-05-23 1998-07-22 Univ Strathclyde Polyamino acid vesicles
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
WO2000068252A1 (en) * 1999-05-10 2000-11-16 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7658926B2 (en) * 2001-09-14 2010-02-09 Opexa Pharmaceuticals, Inc. Autologous T-cell vaccines materials and methods
FR2842422B1 (fr) * 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
WO2004015070A2 (en) * 2002-08-08 2004-02-19 Baylor College Of Medicine Isolation and identification of t cells
US7759055B2 (en) * 2002-08-28 2010-07-20 Millipore Corporation Compositions of solution for sequencing reaction clean-up
US8338648B2 (en) * 2004-06-12 2012-12-25 Signum Biosciences, Inc. Topical compositions and methods for epithelial-related conditions
DE602006020353D1 (de) * 2005-03-24 2011-04-07 Univ Emory Progesterone Dosierungsanweisung in der Behandlung einer traumatischen Verletzung des Gehirns
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
FR2886153B1 (fr) * 2005-05-27 2009-04-10 Gemac Sa Composition destinee au traitement de la sclerose en plaques
PT2016414E (pt) * 2006-05-05 2015-11-24 Opexa Therapeutics Vacina de células t
FR2905868B1 (fr) * 2006-09-18 2012-12-21 Gemac Composition destinee au traitement de la sclerose laterale amyotrophique
RU2432181C2 (ru) 2006-12-22 2011-10-27 Кромафарма Гезельшафт М.Б.Х. Применение полимеров
FR2913335B1 (fr) 2007-03-06 2009-06-05 Michel Geffard Utilisation de conjugues d'acides gras et de poly-l-lysine pour lutter contre des microorganismes pathogenes.
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
CN103458890A (zh) * 2011-04-12 2013-12-18 雀巢产品技术援助有限公司 包括支链脂肪酸的营养组合物及其使用方法
US9994605B2 (en) 2014-03-13 2018-06-12 Universitaet Basel Carbohydrate ligands that bind to IgM antibodies against myelin-associated glycoprotein
FR3030524B1 (fr) 2014-12-17 2017-01-20 Hydro-Fill Utilisation de pll pour ameliorer la stabilite de molecules en solution
CA2996073A1 (en) 2015-09-16 2017-03-23 Universitat Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
FR3048616B1 (fr) 2016-03-14 2018-04-06 Polyneuros Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
FR3122571B1 (fr) * 2021-05-10 2023-05-12 Hydro Fill Tech Compositions et leur utilisation pour rétablir la perméabilité intestinale et/ou prévenir ou lutter contre des maladies multifactorielles
FR3122573B1 (fr) * 2021-05-10 2024-03-29 Hydro Fill Tech Compositions de conjugués poly-lysine et de micelles et/ou de copolymères de poly-lysine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55500053A (https=) * 1978-01-16 1980-01-31
DE3546150A1 (de) * 1985-06-24 1987-01-22 Hoechst Ag Membrananker-wirkstoffkonjugat, seine herstellung sowie seine verwendung
GB9004538D0 (en) * 1990-02-28 1990-04-25 Offord Robin E Chemical compounds
ATE240740T1 (de) * 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
EP0647133A4 (en) * 1992-06-12 1997-10-29 Affymax Tech Nv COMPOSITIONS AND METHODS FOR IMPROVED DRUG DELIVERY.
FR2705234B1 (fr) * 1993-05-19 1995-08-04 Geffard Michel Utilisation de molécules reconnues par des autoanticorps de sérums humains pour le diagnostic ou le traitement du SIDA.

Also Published As

Publication number Publication date
US6114388A (en) 2000-09-05
FR2727117A1 (fr) 1996-05-24
PT792167E (pt) 2001-12-28
WO1996015810A1 (fr) 1996-05-30
DE69521521T2 (de) 2002-04-25
AU694825B2 (en) 1998-07-30
EP0792167A1 (fr) 1997-09-03
EP0792167B1 (fr) 2001-06-27
CA2205557C (en) 2008-07-15
NZ297040A (en) 1999-05-28
AU4181196A (en) 1996-06-17
DE69521521D1 (de) 2001-08-02
ES2161915T3 (es) 2001-12-16
FR2727117B1 (https=) 1997-02-21
CA2205557A1 (en) 1996-05-30
JP4128618B2 (ja) 2008-07-30
ATE202487T1 (de) 2001-07-15
JPH10511643A (ja) 1998-11-10
GR3036710T3 (en) 2001-12-31

Similar Documents

Publication Publication Date Title
DK0792167T3 (da) Monofunktionelle og/eller polyfunktionelle polylysin-konjugater
EE04221B1 (et) Östrogeeni kasutamine ravimi valmistamiseks füüsiliste seisundite raviks menopausijärgsetel isikutel
AU2266297A (en) Recovery of taxanes from conifers
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
PT1042305E (pt) Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
IL130931A0 (en) Small molecules useful in the treatment of inflammatory disease
AU3142597A (en) Dha-pharmaceutical agent conjugates
MY130110A (en) 6-substituted mycophenolic acid and derivatives
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
AU5110490A (en) Immunogenic regions on the e7 protein of human papillomavirus type 16
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
DE69510779D1 (de) Nematizide proteine
NZ305188A (en) DNA encoding Human Papilloma Virus (hPV)type 18
MY117918A (en) Use of an h+, k+- atpase inhibitor in the treatment of nasal polyps
DE69821793D1 (de) Neuronale verwendungen des bmp-11
NO972426L (no) Metode for anvendelse av triarylethylenderivater ved behandling og forhindring av osteoporose
NO970225L (no) Pyridyltioforbindelser for bekjempelse av Helicobacter-bakterier
DE69120287D1 (en) Aminosulfonylharnstoff-acat-inhibitoren
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ES2113734T3 (es) Sistema de forjado para paredes y revestimientos en la construccion.
AU3166295A (en) Imidazopyridine-azolidinones
DE69734237D1 (de) Drogen untersuchungssystem
AU1875395A (en) 4-amino derivatives of 5-substituted mycophenolic acid
GB9409743D0 (en) Curable compositions
DE69726602D1 (en) Hepatitis b inhibitoren